Open Access

Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction

BMC Biotechnology20033:11

DOI: 10.1186/1472-6750-3-11

Received: 20 May 2003

Accepted: 23 July 2003

Published: 23 July 2003



The identification of known mutations in a cell population is important for clinical applications and basic cancer research. In this work an immobilized form of the polymerase chain reaction, referred to as polony technology, was used to detect mutations as well as gene deletions, resulting in loss of heterozygosity (LOH), in cancer cell lines. Specifically, the mutational hotspots in p53, namely codons 175, 245, 248, 249, 273, and 282, and K-ras2, codons 12, 13 and 61, were genotyped in the pancreatic cell line, Panc-1. In addition LOH analysis was also performed for these same two genes in Panc-1 by quantifying the relative gene copy number of p53 and K-ras2.


Using polony technology, Panc-1 was determined to possess only one copy of p53, which possessed a mutation in codon 273, and two copies of K-ras2, one wildtype and one with a mutation in codon 12. To further demonstrate the general approach of this method, polonies were also used to detect K-ras2 mutations in the pancreatic cell lines, AsPc-1 and CAPAN-1.


In conclusion, we have developed an assay that can detect mutations in hotspots of p53 and K-ras2 as well as diagnose LOH in these same genes.


Polony immobilized PCR pancreatic cancer p53 K-ras2 mutations loss of heterozygosity


The advent of the polymerase chain reaction (PCR) played an important role in revolutionizing research in the field of molecular biology [1]. A recent adaptation of this technology, known as polymerase colonies, or "polonies", holds tremendous promise as well. Polony technology is a form of PCR in which the reaction is immobilized in a thin polyacrylamide gel attached to a microscope slide [2, 3]. As the PCR proceeds, the PCR products diffuse radially within the gel from its immobilized template (e.g., genomic DNA), giving rise to a circular PCR product, or polymerase colony. When the gel is stained with SybrGreen I and scanned with a microarray scanner, the polymerase colony resembles a colony on an agar plate, hence its name. Herein, we describe the applications of polony technology to cancer research with the goal of screening for: 1) mutations in key tumor suppressor and oncogenes; as well as 2) loss of heterozygosity.

One of the hallmarks of cancer includes the accumulation of mutations in key genes, namely DNA repair genes [4], tumor suppressor genes [5, 6], and proto-oncogenes [5, 6], accompanied by the loss of the wildtype allele, resulting in loss of heterozygosity [LOH, see reviews by [79]]. Pancreatic cancer, which results in the death of approximately 30,000 Americans annually and is the fourth leading cause of cancer mortalities in the United States, exhibits this hallmark [10]. For example, in pancreatic cancer there is a high incidence of mutations (>50%) in the tumor suppressor genes p16, p53 and DPC4 and approximately 90% of cases coincide with a mutation in the oncogene K-ras2 [see review by [11]]. Furthermore, a significant percentage of tumors harboring a mutated copy of DPC4 or p53 also lose the corresponding wildtype allele, resulting in LOH [see reviews by [11, 12]].

Of particular importance to this study are the genes p53 and K-ras2 since a significant proportion of the mutations are localized to a relatively small number of mutational hotspots [1316]. In this paper we introduce a screen to detect the presence of pancreatic cancer by looking for somatic mutations in p53 and K-ras2 using polony technology to microsequence mutational hotspots within these two genes. In addition polonies are used to diagnose LOH in these same genes.


Previous work has shown that a significant percentage of mutations in p53 and K-ras2 are localized to mutational hotspots, namely codons 175, 245, 248, 249, 273, and 282 in p53 and codons 12, 13, and 61 in K-ras2 [reviewed in [14, 17, 18]]. Each of these mutational hotspots was sequenced in the genomic DNA of various pancreatic cell lines using polony technology as follows. Initially, each exon bearing a mutational hotspot was individually PCR amplified in a polyacrylamide gel giving rise to one polymerase colony, or polony, per copy of genomic p53 or K-ras2 DNA. The non-acrydited strand of the polony was then stripped away after formamide treatment and electrophoresis. A sequencing primer was hybridized to the single-stranded copy of the PCR-amplified p53/K-ras2 fragment and a single base extension with either a Cy-3 or Cy-5 labeled dNTP was performed prior to scanning on a microarray scanner. The process of formamide denaturation, hybridization, and extension was repeated 3 additional times in order to perform an extension with each of the four dNTPs and completely sequence each position.

When all the mutational hotspots were sequenced in the Panc-1 cell line (results of sequencing in Table 3), it was determined that K-ras2 was heterozygous (i.e. one mutant and one wild type allele) at the second position of codon 12 (Figure 1) and p53 harbored a mutation at the second position of codon 273 (Figure 2). In addition to the cell line Panc-1, K-ras2 mutations in the second position of codon 12 were also shown to be present in the cell lines AsPC-1 (G → A; data not shown) and CAPAN-1 (G → T; data not shown). These results are in agreement with previously published data concerning the genotype of these cell lines [1921].
Figure 1

The second position of codon 12 in K-ras2 of Panc-1 genomic DNA is heterozygous with roughly half the alleles being wildtype {G} and with the other half being mutant {A}. (A) All K-ras2 exon1 polonies are shown following Sybr Green I staining. (B) After the polonies were made single-stranded, a sequencing primer was hybridized to the polony and the position was shown to be heterozygous by performing independent single base extensions with Cy-5 labeled: dATP (blue) and dGTP (red). Extensions with Cy-5 labeled dCTP and dUTP did not yield any significant signal (data not shown). Colors are artificial in both images.
Figure 2

The second position of codon 273 in p53 of Panc-1 is mutated, possessing an "A" instead of a "G". (A) All p53 exon 8 polonies are shown following Sybr Green I staining. (B) The position was shown to harbor a G → A mutation by performing independent single base extensions with Cy-5 labeled: dATP (blue) and dGTP (red). Extensions with Cy-5 labeled dCTP and dUTP did not yield any significant signal (data not shown). Colors are artificial in both images.

One hallmark of cancer that can be readily observed using polonies is loss of heterozygosity (LOH). Polony technology provides this capability due to its "digital" nature, where one DNA molecule gives rise to one polony. As a result, polonies can be used to detect changes in gene copy number that arise due to either deletions or multiplications. For example, previous studies have shown that Panc-1 has two copies of K-ras2, but only one copy of p53, due to LOH [20]. When equivalent quantities of Panc-1 genomic DNA were polony amplified, there were approximately twice as many K-ras2 polonies as there were p53 polonies (Figure 3). These results, taken in conjunction with the in situ genotyping shown previously in Figures 2 and 3, clearly demonstrate the ability of polonies to detect LOH. It should be noted that polony amplification of genomic DNA from strains with equal p53 and K-ras2 copy numbers, such as CAPAN-1, yielded equivalent numbers of p53 and K-RAS2 polonies (data not shown). This eliminates the role of primer bias contributing to the distinct number of p53 and K-ras2 polonies amplified in Panc-1 genomic DNA.
Figure 3

Loss of heterozygosity analysis of K-ras2 and p53 in Panc-1. There are approximately twice as many (A) K-ras2 polonies than (B) p53 polonies following the polony amplification of equal amounts of genomic DNA, likely indicating that one of two p53 alleles was lost. These results, coupled with the sequencing of mutational hotspots in these same genes, demonstrate that p53 experienced LOH.


We have shown that polony technology is an improved method to study, and potentially diagnosis, cancer [22]. Specifically, polony technology was successfully applied to both detect intragenic mutations in well-defined mutational hotspots in key cancer genes as well as determine if loss of heterozygosity of these same genes had occurred. For example, Panc-1 was determined to possess only one copy of p53, which possessed an intragenic mutation in codon 273, and two copies of K-ras2, one wildtype and one with an intragenic mutation in codon 12. These results are consistent with findings from previous work [20, 21].

The approach described herein was applied to a clonal cell line. However, this approach could be used to detect rare somatic mutations and to diagnosis cancer with genomic DNA collected from patient samples or biopsies [2327] in a manner similar to Digital PCR developed by Vogelstein and Kinzler [22]. In the case of analyzing pancreatic juice for p53 and K-ras2 mutations, it seems likely that only a small percentage of DNA harbors mutant DNA. However, polonies seem well suited for this type of analysis since several hundred to several million [2] polonies for a particular gene can be analyzed on a single slide, thereby increasing the likelihood of detecting a rare event [22]. Additionally, the frequency of mutations can be readily determined using this approach due to the "digital" nature of polonies.

Finally, it should be noted that this approach is not without limitations. For example, sequencing each mutational hotspot is laborious and detecting mutations outside the hotspots is not feasible. Adherence to mutational hotspots was directly responsible for the inability to detect the p53 mutations in the CAPAN and AsPc-1 cell lines [19, 21]. The best approach for detecting mutations outside the hotspots will involve direct sequencing of the polony PCR products [2, 13, 14].


We have shown that polony technology is an improved method to study, and potentially diagnosis, cancer [22]. Specifically, polony technology was successfully applied to both detect intragenic mutations in well-defined mutational hotspots in key cancer genes as well as determine if loss of heterozygosity of these same genes had occurred. These results are consistent with findings from previous work [20, 21].


Preparation of Pancreatic Cell Line Genomic DNA

The pancreatic cell lines AsPc-1, CAPAN-1 and Panc-1 were purchased from the American Type Culture Collection (Manassas, VA) and were grown according to the manufacturer's instructions [2830]. Genomic DNA was harvested from these cells using a Qiagen (Alameda, CA) Blood and Cell Culture DNA Midi Kit.

Polony gels

Polony gels for genotyping mutational hotspots were cast on Teflon-printed microscope slides as described by Mitra et al [3]. The Teflon-printed, 24.4 × 16.7 mm oval slides (Grace Bio-Labs, Bend, OR) were treated with Bind Silane (Amersham, Piscataway, NJ) in accordance with the manufacture's instructions. The slides were stored in a desiccator. To cast the polyacrylamide gels used for the immobilized PCR reaction, a master mix was first made for 12 polony gels (131.0 μL of filter-sterilized doubly deionized water, 25.5 μL of 10X JumpStart Taq Polymerase Reaction Buffer (Sigma, St. Louis, MO), 2.55 μL of dNTP (20 mM each), 1.5 μL of 30% BSA (Sigma), 2.55 μL 10% Tween 20, and 56.16 μL of degassed, filter-sterilized acrylamide). For each position within a mutational hotspot to be genotyped, 20 μL of master mix was combined with 1 μL of genomic DNA as well as 0.23 μL of each the forward and reverse primers (50 μM each; see Table 1) designed to polony amplify the portion of the exon bearing the mutational hotspot(s). Depending on whether the sense or anti-sense strand was to be sequenced, either the forward or reverse primer was modified with a 5' acrydite to covalently attach the PCR product to the acrylamide matrix (see below). Immediately prior to casting the polony gel, 1.38 μL of JumpStart Taq Polymerase (Sigma), 0.34 μL of 5% APS, and 0.34 μL of TEMED was added to the master mix/primer/DNA solution. The gel was polymerized for 10 min, a hybrid well cover (Grace Bio-labs) was placed on top of the gel and light mineral was pipeted into the hybrid well chamber. The slide was placed in a placed in an in situ PCR tower (MJ Research, MA) and thermalcycled (94 C for 2 min; 39 cycles of 94 C for 15 s, (Tm-3) C for 30 s and 72 C for 30 s; final extension at 72 C for 2 min). (Note: Tm is the melting temperature of the PCR primer with the lower melting temperature in a given primer pairing.)
Table 1

Primers used to polony amplify p53 and K-ras 2 exons bearing mutational hotspots from pancreatic cancer cell line genomic DNA.

Primer Name


p53 exon5 forward


p53 exon5 reverse


p53 exon7 forward


p53 exon7 reverse


p53 exon8 forward


p53 exon8 reverse


kras exon1 forward


kras exon1 reverse


kras exon2 forward


kras exon2 reverse


Upon completion of the PCR reaction, the slide was immersed in clean hexane to remove oil prior to staining in 2X Sybr Green (Molecular Probes, Eugene, OR) for 15 minutes. The slides was then washed in TBE and scanned with a ScanArray 5000 microarray scanner (Perkin Elmer, Wellesley, MA) with the FITC laser and filter set.

Denaturation and electrophoresis of polony gels

Prior to genotyping, the double stranded polonies were made single stranded by stripping away the non-acrydited strand in a two-step procedure [3]. The polony DNA was denatured by incubation in a formamide buffer (1x SSC, 70% formamide, 25% doubly deionized-water) at 70 C for 15 min. Immediately following denaturation, the gels were subjected to electrophoresis (42 % urea in 0.5x TBE) to remove the non-acrydited strand.

Hybridization and single base extension

After electrophoresis, the polony slides were washed 4× in wash 1E (0.1 M Tris-HCl, pH 7.5, 20 mM EDTA, 0.5 M KCl) to prepare for hybridization of the sequencing primer. 200 μL of annealing buffer (6x SSPE, 0.01% Triton X-100) containing 0.5 μM primer (Table 2) was then pipeted onto the gel and covered with a hybrid well chamber. The slide was then incubated for 2 min at 94 C followed by 20 min at (Tm-3) C to facilitate hybridization.
Table 2

Primers used to sequence codons in p53 and K-ras2 that experience a high incidence of mutation during carcinogenesis. The designations "for" and "rev" indicate whether the anti-sense or sense strand was sequenced, respectively.

Primer Name


p53 c175 pos1 for


p53 c175 pos2 for


p53 c175 pos3 for


p53 c175 pos3 rev


p53 c175 pos2 rev


p53 c245 pos1 for


p53 c245 pos2 for


p53 c245 pos3 for


p53 c248 pos1 for


p53 c248 pos2 for


p53 c248 pos3 for


p53 c249 pos3 rev


p53 c249 pos2 rev


p53 c249 pos1 rev


p53 c273 pos1 for


p53 c273 pos2 for


p53 c273 pos3 for


p53 c282 pos1 for


p53 c282 pos2 for


p53 c282 pos3 for


kras c12 pos1 for


kras c12 pos2 for


kras c12 pos3 for


kras c13 pos3 rev


kras c13 pos2 rev


kras c13 pos1 rev


kras c61 pos1 for


kras c61 pos2 for


kras c61 pos3 for


Table 3

Results from sequencing p53 and K-ras 2 mutational hotspots in Panc-1 genomic DNA.




strand sequenced


















strand sequenced



























Genotyping of mutational hotspots was finally accomplished by performing single base extensions of the hybridized sequencing primer with fluorescently labeled deoxynucleotides. Following hybridization, the gels were washed 2× in Wash1E and then equilibrated in Klenow extension buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 0.01% Triton X-100) for 1 minute. For each sample, 50 μL solution containing approximately 5 units of Klenow large fragment (New England Biolabs, Beverly, MA), 3 μg of single stranded binding protein (US Biochemicals, Cleveland, OH), and 0.5 μM Cy3- or Cy5-labeled dATP, dCTP, dGTP or dUTP (Perkin Elmer) was pipeted onto the gel. The single base extension was allowed to proceed for 2 min. The gels were then washed in Wash1E to reduce background fluorescence and scanned on the ScanArray5000 with the appropriate lasers and filters. The process of formamide denaturation, hybridization, extension, and scanning was repeated 3 additional times for each primer in order to do a single base extension with each of the four labeled nucleotides.



A PC-formatted CD-ROM containing this manuscript is included. The manuscript was created in Microsoft Word XP in Office XP for the PC.


The authors would like to thank Kevin Duffy from Eric Wickstrom's laboratory for growing the AsPc-1, CAPAN-1, and Panc-1 cell lines used in these experiments. In addition, the authors would like to acknowledge George Church and Robi Mitra for assistance with polony technology. Finally, the authors would like to thank Joshua Merritt and Venugopal Mikkilineni helpful discussions and technical assistance. This work was supported by the University of Delaware Research Foundation, the NIH and the US Department of Energy Office of Biological and Environmental Research.

Authors’ Affiliations

Department of Chemical Engineering, University of Delaware
Department of Biochemistry and Molecular Pharmacology, Thomas Jefferson University


  1. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N: Enzymatic Amplification of Beta-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle-Cell Anemia. Science. 1985, 230: 1350-1354.View ArticleGoogle Scholar
  2. Mitra RD, Church GM: In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res. 1999, 27: e34-10.1093/nar/27.24.e34.View ArticleGoogle Scholar
  3. Mitra RD, Butty VL, Shendure J, Williams BR, Housman DE, Church GM: Digital genotyping and haplotyping with polymerase colonies. Proc Natl Acad Sci U S A. 2003, 100: 5926-5931. 10.1073/pnas.0936399100.View ArticleGoogle Scholar
  4. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature. 2001, 411: 366-374. 10.1038/35077232.View ArticleGoogle Scholar
  5. Ponder BA: Cancer genetics. Nature. 2001, 411: 336-341. 10.1038/35077207.View ArticleGoogle Scholar
  6. Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 2001, 411: 342-348. 10.1038/35077213.View ArticleGoogle Scholar
  7. Fearon ER: Tumor-Suppressor Genes. The Genetic Basis of Human Cancer. Edited by: Kinzler KW and Vogelstein V. 2002, The McGrw-Hill Companies, 197-206.Google Scholar
  8. Kinzler KW, Vogelstein V: Introduction. The Genetic Basis of Human Cancer. Edited by: Kinzler KW and Vogelstein V. 2002, The McGraw-Hill CompaniesGoogle Scholar
  9. Park M: Oncogenes. The Genetic Basis of Human Cancer. Edited by: Kinzler KW and Vogelstein V. 2002, The McGraw-Hill Companies, 177-196.Google Scholar
  10. Cancer Facts & Figures 2003. 2003, Atlanta, American Cancer Society, 52-
  11. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE: Molecular pathology of pancreatic cancer. Cancer Journal. 2001, 7: 251-258.Google Scholar
  12. Wilentz RE, Argani P, Hruban RH: Loss of heterozygosity or intragenic mutation, which comes first?. Am. J. Pathol. 2001, 158: 1561-1563.View ArticleGoogle Scholar
  13. Glazko GV, Rogozin IB, Glazko VI: Mutational hotspots in the p53 gene revealed by classification analysis. Exp. Oncol. 2002, 24: 32-37.Google Scholar
  14. Harris CC: 1995 Deichmann Lecture - p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol. Lett. 1995, 82-3: 1-7. 10.1016/0378-4274(95)03643-1.View ArticleGoogle Scholar
  15. Yanez L, Groffen J, Valenzuela DM: C-K-Ras Mutations in Human Carcinomas Occur Preferentially in Codon-12. Oncogene. 1987, 1: 315-318.Google Scholar
  16. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most Human Carcinomas of the Exocrine Pancreas Contain Mutant C-K-Ras Genes. Cell. 1988, 53: 549-554.View ArticleGoogle Scholar
  17. Land H, Parada LF, Weinberg RA: Cellular Oncogenes and Multistep Carcinogenesis. Science. 1983, 222: 771-778.View ArticleGoogle Scholar
  18. Cooper GM: Cellular Transforming Genes. Science. 1982, 217: 801-806.View ArticleGoogle Scholar
  19. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M, Scarpa A: Genetic profile of 22 pancreatic carcinoma cell lines - Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. Int. J. Pathol. 2001, 439: 798-802.View ArticleGoogle Scholar
  20. Sun CL, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A: Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol. Rep. 2001, 8: 89-92.Google Scholar
  21. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M: Comparative-Analysis of Mutations in the P53 and K-Ras Genes in Pancreatic-Cancer. Int. J. Cancer. 1994, 58: 185-191.View ArticleGoogle Scholar
  22. Vogelstein B, Kinzler KW: Digital PCR. Proc Natl Acad Sci U S A. 1999, 96: 9236-9241. 10.1073/pnas.96.16.9236.View ArticleGoogle Scholar
  23. Wang Y, Yamaguchi Y, Watanabe H, Ohtsubo K, Wakabayashi T, Sawabu N: Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K-ras mutation. J. Gastroenterol. 2002, 37: 831-839. 10.1007/s005350200137.View ArticleGoogle Scholar
  24. Ha A, Watanabe H, Yamaguchi Y, Ohtsubo K, Wang Y, Motoo Y, Okai T, Wakabayahi T, Sawabu N: Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. Pancreas. 2001, 23: 356-363. 10.1097/00006676-200111000-00004.View ArticleGoogle Scholar
  25. Queneau PE, Adessi GL, Thibault P, Cleau D, Heyd B, Mantion G, Carayon P: Early detection of pancreatic cancer in patients with chronic pancreatitis: Diagnostic utility of a K-ras point mutation in the pancreatic juice. Am. J. Gastroenterol. 2001, 96: 700-704. 10.1016/S0002-9270(00)02401-1.View ArticleGoogle Scholar
  26. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ: Detection of Ras Gene-Mutations in Pancreatic-Juice and Peripheral-Blood of Patients with Pancreatic Adenocarcinoma. Cancer Res. 1993, 53: 2472-2474.Google Scholar
  27. Berthelemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L: Identification of K-Ras Mutations in Pancreatic-Juice in the Early Diagnosis of Pancreatic-Cancer. Ann. Intern. Med. 1995, 123: 188-191.View ArticleGoogle Scholar
  28. Lieber M, Zzetta J, Lsonrees W, Plan M, Daro G: Establishment of a Continuous Tumor-Cell Line (Panc-1) from a Human Carcinoma of Exocrine Pancreas. Int. J. Cancer. 1975, 15: 741-747.View ArticleGoogle Scholar
  29. Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, Berjian R, Douglass HO, Martin EW, Chu TM: Human Pancreatic Adenocarcinoma - Invitro and Invivo Morphology of a New Tumor Line Established from Ascites. In Vitro-Journal of the Tissue Culture Association. 1982, 18: 24-34.Google Scholar
  30. Fogh J, Wright WC, Loveless JD: Absence of Hela-Cell Contamination in 169 Cell Lines Derived from Human Tumors. J. Natl. Cancer Inst. 1977, 58: 209-214.Google Scholar


© Butz et al; licensee BioMed Central Ltd. 2003

This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.